Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales

Reuters
04 Jun
Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales

Immix Biopharma Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to offer and sell shares of its common stock at its discretion through the agent. The sales will be conducted under the company's effective Registration Statement on Form S-3. The agent will earn a commission of 3% on the gross sales proceeds and will also be reimbursed for certain specified expenses up to $50,000. The agreement enables Immix Biopharma to strategically sell shares in alignment with market conditions and company requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013417), on June 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10